HopeStage
Back to all studies
CompletedNCT00305422

Quetiapine or risperidone for negative symptoms and cognition in schizophrenia

About this titleRead the official source — NCT00305422
Medication studyAges 18–65Germany
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
MunichSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateNovember 2001
Recruitment status
Completed
Enrollment listed in the registry
45
Sponsor
AstraZeneca
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Germany
Age range
From 18 Years to 65 Years
Official registry ID
NCT00305422
Official title
Show the full official title

Efficacy of Quetiapine Compared to Risperidone on Negative Symptoms and Cognition With Regard to Underlying Neurobiological Mechanisms and Brain Activation.

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Munich

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is AstraZeneca.

Did this study involve medication?

Yes. The study involved medication, including Quetiapine fumarate and Risperidone.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies